Extrapyramidal side effects are unacceptable
- 28 September 2001
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 11, S397-S403
- https://doi.org/10.1016/s0924-977x(01)00109-2
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999
- Compliance With Medication Regimens for Mental and Physical DisordersPsychiatric Services, 1998
- Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboBiological Psychiatry, 1997
- Incidence and Correlates of Tardive Dyskinesia in First Episode of SchizophreniaArchives of General Psychiatry, 1996
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- A two-year prospective study of treatment compliance in patients with schizophreniaPsychological Medicine, 1992
- Tardive akathisia: An analysis of clinical features and response to open therapeutic trialsMovement Disorders, 1989
- A 5-Year Prospective Longitudinal Study of Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1988
- Akathisia Variants and Tardive DyskinesiaArchives of General Psychiatry, 1985
- Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic DrugsAmerican Journal of Psychiatry, 1980